TARS (Tarsus Pharmaceuticals) Institutional Ownership: 110.51% (As of Jul. 04, 2026)


TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $65.44
GF Value $203.67
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Institutional Ownership?

Tarsus Pharmaceuticals TARS +7.47% 47 Institutional Ownership is 110.51% as of Jul. 04, 2026. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $203.67 (Possible Value Trap). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tarsus Pharmaceuticals's institutional ownership is 110.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tarsus Pharmaceuticals's Insider Ownership is 4.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tarsus Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 96.76%.

Tarsus Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Institutional Ownership Chart

Tarsus Pharmaceuticals Historical Data

The historical data trend for Tarsus Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 46.72 47.93 48.85 50.50 49.70 50.35 48.26 47.74 46.75 47.31
TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 110.51% mean?
Tarsus Pharmaceuticals (TARS) has a Institutional Ownership of 110.51% as of Jul. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Institutional Ownership too high?
Tarsus Pharmaceuticals' current Institutional Ownership is 110.51%. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Institutional Ownership compare to KLRA and CLDX?
Tarsus Pharmaceuticals' Institutional Ownership of 110.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Institutional Ownership is 110.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $203.67, compared to a current price of $65.44 — trading 67.9% below its estimated fair value. The current Institutional Ownership is 110.51%. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Institutional Ownership is 110.51% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $65.44 is trading 67.9% below its estimated GF Value™ of $203.67. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Institutional Ownership: 110.51%
  • GF Value™: $203.67 vs. price of $65.44 (67.9% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.44
Price
$203.67
GF Value